Former acting DHS Secretary Chad Wolf warned that unapproved peptides linked to Chinese chemical firms may be entering the U.S. by using distribution networks similar to those exploited for fentanyl precursors. The FDA cannot verify the safety or quality of unapproved GLP-1 products, and a September import alert allows detention of certain bulk GLP-1 substances. The alert follows reporting on a counterfeit Ozempic scheme allegedly traced to China, and Wolf called for coordinated federal action from CBP, DOJ, DHS and the FDA.
Former Acting DHS Secretary Warns China-Linked Peptides May Be Entering U.S.; Calls For Coordinated Federal Response
Expert warns China-linked peptides could pose US risk
Former acting Department of Homeland Security Secretary Chad Wolf is warning that unapproved peptides linked to Chinese chemical companies could be entering the United States as demand for weight-loss drugs soars. Wolf told NewsNation that some firms tied to fentanyl precursor production may be exploiting the same international networks to move peptides into U.S. markets.
"This is a really serious issue,"Wolf told NewsNation's Lauren Wright, adding that many of these peptides are not approved by the Food and Drug Administration and therefore their safety and quality cannot be verified.
The FDA has cautioned consumers that unapproved GLP-1 products—used by some for weight loss—have not undergone the agency's review for safety, effectiveness or manufacturing quality. In response to concerns about imported ingredients, the agency issued a September import alert that allows certain bulk GLP-1 drug substances to be detained without physical examination, although some manufacturers or shipments may qualify for exclusion.
Wolf compared aspects of the peptides supply chain to networks U.S. authorities confronted during the fentanyl crisis, noting that while peptides and illicit fentanyl are very different substances with distinct risks, similar distribution channels and intermediaries can be involved.
The warning follows NewsNation reporting that a counterfeit Ozempic (semaglutide) operation was allegedly traced to China. Federal prosecutors said two Indian nationals were charged in an international scheme involving counterfeit versions of the diabetes and weight-loss medication. Wolf described how questionable peptide products can move from Chinese chemical producers through U.S. middlemen and then be repackaged or mislabeled before reaching consumers.
Over 1.1 million people are reportedly using GLP-1 drugs without an FDA-approved reason, heightening concerns about unregulated supply chains and consumer safety.
To stem the flow of unapproved or counterfeit products, Wolf urged a unified federal response—from Customs and Border Protection and the Department of Justice to DHS, the FDA and other agencies—to improve detection, enforcement and public warnings.
Note: The FDA has approved certain GLP-1 therapies for specific medical indications; however, unapproved versions and mislabeled products have not undergone the agency's full safety and efficacy review.
Help us improve.
